Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara M Tolaney

Showing results (71-80 of 372) with videos related to

Pageof 38
Sort By:
Nature Reviews. Cancer|October 2, 2025
Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatmentAlfred Zippelius, Sara M Tolaney, Paolo Tarantino, et al.
The Oncologist|September 26, 2025
Clinical perspective on management of key adverse events with sacituzumab govitecanSara M Tolaney, Guru P Sonpavde, Paolo Tarantino, et al.
Future Oncology (London, England)|October 3, 2023
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer: plain language summary of the monarcHER studySara M Tolaney, Shom Goel, Adams Kusi Appiah, et al.
Current Oncology Reports|January 10, 2024
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better?Fei Song, Paolo Tarantino, Ana Garrido-Castro, et al.
Oncology and Therapy|July 24, 2020
Integration of Physician and Nursing Professional Efforts to Deliver Supportive Scalp Cooling Care to Oncology Patients at Risk for AlopeciaLindsay L Peterson, Maryam Lustberg, Sara M Tolaney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 30, 2023
Reply to Y. Yoshitomi et alSara M Tolaney, Elisabeth De Kermadec, Patrick Cohen, et al.
Cancer Treatment Reviews|March 9, 2023
Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature reviewVolkmar Müller, Rupert Bartsch, Nancy U Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2006
Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancerSara M Tolaney, Ann H Partridge, Rochelle G Sheib, et al.
Breast Cancer Research and Treatment|January 9, 2022
Factors leading to alpelisib discontinuation in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative breast cancerYee-Ming M Cheung, Grace E Cromwell, Sara M Tolaney, et al.
The Lancet. Oncology|May 5, 2023
Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer - Authors' replyStephen R D Johnston, Sara M Tolaney, Joyce O'Shaughnessy, et al.
Pageof 38

Showing results (71-80 of 372) with videos related to

Sort By:
Pageof 38
Nature Reviews. Cancer|October 2, 2025
Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatmentAlfred Zippelius, Sara M Tolaney, Paolo Tarantino, et al.
The Oncologist|September 26, 2025
Clinical perspective on management of key adverse events with sacituzumab govitecanSara M Tolaney, Guru P Sonpavde, Paolo Tarantino, et al.
Future Oncology (London, England)|October 3, 2023
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer: plain language summary of the monarcHER studySara M Tolaney, Shom Goel, Adams Kusi Appiah, et al.
Current Oncology Reports|January 10, 2024
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better?Fei Song, Paolo Tarantino, Ana Garrido-Castro, et al.
Oncology and Therapy|July 24, 2020
Integration of Physician and Nursing Professional Efforts to Deliver Supportive Scalp Cooling Care to Oncology Patients at Risk for AlopeciaLindsay L Peterson, Maryam Lustberg, Sara M Tolaney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 30, 2023
Reply to Y. Yoshitomi et alSara M Tolaney, Elisabeth De Kermadec, Patrick Cohen, et al.
Cancer Treatment Reviews|March 9, 2023
Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature reviewVolkmar Müller, Rupert Bartsch, Nancy U Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2006
Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancerSara M Tolaney, Ann H Partridge, Rochelle G Sheib, et al.
Breast Cancer Research and Treatment|January 9, 2022
Factors leading to alpelisib discontinuation in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative breast cancerYee-Ming M Cheung, Grace E Cromwell, Sara M Tolaney, et al.
The Lancet. Oncology|May 5, 2023
Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer - Authors' replyStephen R D Johnston, Sara M Tolaney, Joyce O'Shaughnessy, et al.
Pageof 38